Clinical Trial Update: A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis [Phase 3]

View source ↗

Summary

Phase 3 long-term efficacy and safety study of ixekizumab in active psoriatic arthritis has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Ixekizumab (ixekizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Psoriatic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2019-11-15